Blue Trust Inc’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History

Blue Trust Inc’s Portfolio LABT Stock Details LABT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11	Hold	11	–	–	﹤0.01%	2509
2026 Q2	$35	Buy	+11	New	+$189	﹤0.01%	2429

Blue Trust Inc's LABT Position: Q3 2026 in Review

Blue Trust Inc held its Lakewood-Amedex Biotherapeutics (LABT) position steady in Q3 2026 at 11 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #2509.

Blue Trust Inc first reported a position in LABT in Q2 2026 and has held it in 2 quarters since. The position peaked at $35 in Q2 2026. 1 fund tracked by Wall St. Rank holds LABT as of Q3 2026.

Blue Trust Inc held 11 shares of Lakewood-Amedex Biotherapeutics worth $11 as of Q3 2026.
Blue Trust Inc left its Lakewood-Amedex Biotherapeutics share count unchanged in Q3 2026.
Lakewood-Amedex Biotherapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q3 2026, its #2509 holding.
Blue Trust Inc first reported a position in Lakewood-Amedex Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
Blue Trust Inc's Lakewood-Amedex Biotherapeutics position peaked at $35 in Q2 2026.
1 fund tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q3 2026.

Based on Blue Trust Inc's 13F filing for Q3 2026, filed 15 Oct 2026.